Kymera Therapeutics, Inc. (KYMR) · Oct 29, 2026 · Earnings
Miss — EPS -$1.32 vs -$1.27 consensus; revenue $0 vs ~$3.10M consensus
Kymera’s third-quarter earnings missed consensus, but new KT-579 Phase 1 data strengthen the company’s oral immunology pipeline ahead of lupus testing.
Kymera is a cash-rich clinical-stage biotech building oral protein degraders for immunology, with KT-621 moving toward Phase 3 in atopic dermatitis and KT-579 emerging as a new lupus and autoimmune program. Its core commercial question is still clinical validation, not near-term revenue; the company’s pipeline is centered on STAT6 and IRF5 degraders, while partnered programs with Sanofi and Gilead provide additional optionality.
The quarter itself missed the published financial bar. Kymera reported a third-quarter loss of $1.32 per share versus a published consensus of roughly $1.27, while collaboration revenue was zero against an external estimate of about $3.10 million. The revenue shortfall is not a sign of a broken operating model so much as the absence of another Gilead-related collaboration-revenue recognition event; the company explicitly says it does not expect additional collaboration revenue in 2026.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| EPS (Financial Results) | -$1.32 | -$0.94 | -$1.27 |
| Collaboration revenue (Financial Results) | $0 | $2.8M | $3.10M |
| R&D expense (Financial Results) | $128.5M (+73.5%) | $74.1M | |
| Net loss (Financial Results) | $132.0M (+60.6%) | $82.2M | |
| Cash and investments (Balance Sheet) | $1.646B (+1.6% vs. Dec. 2025) | $1.619B |
The more important update is KT-579’s first human proof of mechanism. The IRF5 degrader produced at least 90% median degradation across multiple dose levels, including in skin as well as blood, and suppressed several disease-relevant inflammatory biomarkers by 87% to 98% at Day 14. 〔0〕 That is meaningfully better than a routine safety-only Phase 1 readout because it shows target engagement, tissue activity and downstream pathway suppression in the same study.
Safety supports advancing the program, but the evidence is still biological rather than clinical. The filing reports no serious or severe adverse events, no discontinuations and no clinically relevant changes in vital signs, laboratory tests or ECGs. 〔1〕 The next test is whether those biomarker effects translate into patient benefit in the roughly 30-person LUMORA Phase 1b lupus study, planned for early 2027—not whether KT-579 can yet be judged effective in lupus.
KT-621 remains the nearer-term value driver. The last patient completed the week-16 visit in the BROADEN2 Phase 2b atopic dermatitis trial, with topline data still expected by year-end 2026, while the company continues its asthma Phase 2b study. The filing therefore adds a strong new early-stage asset without changing the immediate hierarchy of catalysts: KT-621’s Phase 2b efficacy data matter more to the business than KT-579’s healthy-volunteer biomarkers.
Funding is not the constraint created by this quarter. Kymera ended September with $1.6 billion in cash, cash equivalents and investments and says the balance funds operations into 2029. That cushion allows the company to keep spending heavily on STAT6, IRF5 and discovery programs, but it also means the widening quarterly loss reflects deliberate pipeline investment rather than an imminent financing need.
Bottom line: The earnings print missed a modest financial expectation, but the clinically more consequential news is that KT-579 produced unusually deep target degradation with a clean Phase 1 safety profile. The quarter is mixed overall: weaker reported numbers, stronger evidence that Kymera’s second major immunology program is working as designed.
Next catalyst: KT-621 BROADEN2 topline data by year-end 2026.
KT-621 BROADEN2 topline data, by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!